Zoetis Inc. (ZTS) fair value analysis
S&P 500 · Updated 2026-10-19
ZTS price how computed
Forward Fair Value verdict
UndervaluedZTS is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $74.81
- Sector
- Healthcare
- 12-month range
- $69.10–$147.53
- Market cap
- $30.9B
- From 52-week high
- -49.3%
- Shares outstanding
- 413M
- Rank in Healthcare by discount to fair value
- #98 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Zoetis Inc. is a pharmaceutical company that discovers, develops, manufactures, and distributes medicines and vaccines for animals, including both companion animals such as dogs and cats and livestock such as cattle and poultry. The company operates globally across multiple continents, serving veterinarians, farmers, and animal owners in markets around the world.
ZTS currently ranks #98 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $30.9B
- P/E (trailing)
- 11x
- Revenue (TTM)
- $9.52B
- Net margin
- 27.5%
- EPS (TTM)
- $6.58
- Gross margin
- 72.7%
- Debt / equity
- 2.93
- Revenue growth (3-yr avg)
- 4.9%
- Shares outstanding
- 413M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Stable
- 52-week position
- The bottom quarter of its range
- DCF cross-check
- Fairly Valued
Technicals how computed
- RSI (14-day)
- 68 · neutral
- 50-day average
- $73.98
- 200-day average
- $95.87
- Moving-average state
- 50-day below 200-day (death cross state); price between the averages
Dividends how computed
- Paid, last 12 months
- $2.09 per share (4 payments)
- Yield on last price
- 2.79%
- Consecutive years of increases
- 12
- Next ex-dividend date
- 2026-10-30
- Last payment date
- 2026-09-01
Earnings how computed
- Next earnings report
- 2026-11-05 (pre-market)
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+1.6%)
2026-03 ▼ miss (-5.6%)
2025-12 ▲ beat (+5.7%)
2025-09 ▲ beat (+4.9%)
2025-06 ▲ beat (+9.3%)
2025-03 ▲ beat (+5.7%)
2024-12 ▲ beat (+2.9%)
2024-09 ▲ beat (+8.2%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 8 buy · 9 hold · 0 sell (17 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $94.4
- Target vs last price
- +26.2%
What our data shows for ZTS
- Our model validated 17 trailing price-to-earnings windows for ZTS, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $69.10–$147.53.
- The 14-day relative strength index sits at a neutral 68.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for ZTS
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent ZTS news
TickrTrends' derived news-sentiment signal for ZTS is currently leaning positive, computed from recent coverage.
- Zoetis (ZTS) Gains FDA Approval for Convenia RTU for Dogs, Enhancing Treatment Convenience (gurufocus.com, 2026-10-20)
TickrTrends take: Zoetis received FDA approval for Convenia RTU for dogs, a ready-to-use formulation that simplifies administration compared to previous versions and may expand the product's addressable market through improved convenience and adoption rates. Given TickrTrends' current undervalued assessment of ZTS, this approval represents a potential revenue catalyst for an established product line that could strengthen the company's competitive position in the veterinary pharmaceuticals market. Investors focused on valuation should monitor whether this formulation enhancement translates into meaningful market share gains or pricing power within the healthcare sector's animal health segment. - ZTS Downgraded by Jefferies -- Price Target Lowered to $83.00 (gurufocus.com, 2026-10-20)
TickrTrends take: Jefferies' downgrade and reduced price target of $83 represent a significant reassessment of Zoetis that contrasts with TickrTrends' current undervalued classification for the Healthcare sector company. The gap between the analyst's new $83 target and the market's current pricing creates a key metric for valuation-focused investors to monitor, as it suggests potential tension between institutional analyst sentiment and quantitative valuation models. Investors relying on fundamental valuation analysis should track whether the downgrade reflects concerns about earnings sustainability or whether it presents a divergence worth examining further against the company's actual business performance. - Zoetis’ Valuation Has Fallen Sharply, but Has the Market Overreacted? (insidermonkey.com, 2026-10-16)
TickrTrends take: Zoetis operates in the Healthcare sector where TickrTrends currently derives an Undervalued verdict for the stock, suggesting the market may have indeed overreacted to recent valuation pressures. Investors focused on valuation metrics should monitor whether the sharp decline reflects fundamental deterioration in the company's business prospects or represents a timing opportunity created by broader market sentiment. The gap between current market pricing and TickrTrends' assessment indicates there may be meaningful variance between how the market is currently valuing the company and what fundamental analysis suggests is appropriate.
More ZTS news
- ZTS Initiated Coverage by Goldman Sachs -- Price Target Announced at $74 (gurufocus.com, 2026-10-16)
- Zoetis Inc (ZTS) Stock Up 4.2% and Still Undervalued -- GF Score: 71/100 (gurufocus.com, 2026-10-15)
- Zoetis (ZTS) Expands Board to 13 Members with Appointment of Iris Knobloch (gurufocus.com, 2026-10-13)
- Zoetis' Simparica Trio Shows Superior Heartworm Protection; ZTS Dividend Remains Attractive (gurufocus.com, 2026-10-06)
- Zoetis (ZTS) Has a Huge Animal Health Moat. Is It Starting to Crack? (insidermonkey.com, 2026-10-02)
- Zoetis: Priced For The Worst, Worth Buying (NYSE:ZTS) (seekingalpha.com, 2026-09-30)
What people are saying
Follow the ZTS conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for ZTS show a shift this week in the DCF cross-check band assessment, which moved from undervalued to fairly valued. Despite this change in the DCF metric, the current overall valuation verdict for ZTS remains undervalued. ZTS operates within the Healthcare sector.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is ZTS stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), ZTS is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is ZTS's TickrTrends verdict?
ZTS's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does ZTS compare to other Healthcare stocks?
ZTS ranks #98 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is ZTS overbought or oversold?
ZTS's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does ZTS pay a dividend?
Yes. ZTS paid $2.09 per share over the last twelve months (4 payments), a 2.79% yield on TickrTrends' last price, and has raised the annual total for 12 consecutive years. The next ex-dividend date on file is 2026-10-30.
When does ZTS report earnings next?
ZTS's next earnings report is scheduled for 2026-11-05 (pre-market), per the published earnings calendar.
Does ZTS usually beat earnings estimates?
Over its last 8 reported quarters ZTS beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ZTS?
Of 17 analysts covering ZTS, 8 rate it a buy, 9 a hold and 0 a sell - hold-leaning, with a consensus price target of $94.4 (+26.2% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
ZTS vs ADMA · ZTS vs ALGN · ZTS vs ANIP · ZTS vs ASTH · ZTS vs AZN